Top-Down Treatment Superior for Crohn Disease
By Lori Solomon HealthDay Reporter
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a study published online Feb. 22 in The Lancet Gastroenterology & Hepatology.
Nurulamin M. Noor, Ph.D., from the University of Cambridge in the United Kingdom, and colleagues evaluated the use of a putative prognostic biomarker to guide Crohn disease therapy. The analysis included patients randomly assigned to either top-down (189; i.e., early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (190; conventional) treatment strategies.
The researchers found no biomarker–treatment interaction effect (absolute difference, 1 percentage point; 95 percent confidence interval, –15 to 15). In the top-down group, sustained steroid-free and surgery-free remission were significantly more frequent than in the accelerated step-up group (79 versus 15 percent). The top-down group also had fewer adverse events (including disease flares) and serious adverse events versus the accelerated step-up group (adverse events: 168 versus 315; serious adverse events: 15 versus 42), including fewer complications requiring abdominal surgery (one versus 10). There were no differences in serious infections (three versus eight).
"Top-down treatment should be considered standard of care for patients with newly diagnosed active Crohn's disease," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
Study IDs Risk Factors for Extraintestinal Manifestations of IBD
WEDNESDAY, April 17, 2024 -- Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD)...
Higher Vitamin D Levels Cut Bowel Resection Risk With IBD
WEDNESDAY, April 3, 2024 (HealthDay News) -- An increased serum level of 25-hydroxyvitamin D (25[OH]D) is independently associated with a lower risk for bowel resection with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.